This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Illumina (ILMN) Q1 Earnings Beat Estimates, Gross Margin Down
by Zacks Equity Research
Illumina (ILMN) ended the first quarter with better-than-expected earnings and revenues on strength in Core Illumina and the GRAIL businesses driving the top line.
Avanos Medical (AVNS) Q1 Earnings, Revenues Top Estimates
by Zacks Equity Research
Avanos Medical's (AVNS) first-quarter 2022 results reflect strength in the Pain Management segment.
Vertex (VRTX) Q1 Earnings Lag, Sales Top, Expense View Tweaked
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) earnings miss estimates while sales beat the same for the first quarter of 2022. The company maintains its revenue guidance for 2022.
Phibro (PAHC) Q3 Earnings Lag Estimates, 2022 Revenue View Up
by Zacks Equity Research
In Q3, Phirbo (PAHC) reports growth in the Animal Health business on higher sales of processing aids, which are used to improve production efficiency in the ethanol fermentation industry.
DaVita (DVA) Misses on Q1 Earnings, Reiterates FY22 EPS View
by Zacks Equity Research
Despite strength in dialysis patient service revenues, DaVita (DVA) records an overall soft Q1 performance.
Karuna Therapeutics (KRTX) Posts Narrower-Than-Expected Q1 Loss
by Zacks Equity Research
Karuna Therapeutics' (KRTX) first-quarter 2022 earnings beat estimates. Due to lack of marketed products in its portfolio, KRTX did not record any revenues during the quarter.
Allogene (ALLO) Q1 Earnings Beat, Pipeline Progresses Well
by Zacks Equity Research
Allogene's (ALLO) first-quarter earnings beat estimates. Upon removal of the FDA's clinical hold on its AlloCAR T candidates, ALLO continues to move forward with its pipeline.
Mirati (MRTX) Q1 Loss Wider Than Expected, Sales Beat
by Zacks Equity Research
Mirati Therapeutics (MRTX) reports wider-than-expected Q1 loss while revenues beat the mark. MRTX plans to enter two new candidates into early-stage clinical studies in second-half 2022.
Thermo Fisher (TMO) End Markets Strong, Margin Under Pressure
by Zacks Equity Research
Thermo Fisher's (TMO) core business strength was broad-based across segments, end markets, and geographies.
Amarin (AMRN) Q1 Earnings & Sales Hurt by Vascepa Generics
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and COVID-related disruptions during the first quarter. The company's stock falls significantly on May 4.
Quidel (QDEL) Q1 Earnings, Revenues Surpass Estimates, Up Y/Y
by Zacks Equity Research
Quidel's (QDEL) robust performance across two of its product categories drives its first-quarter 2022 top line.
CONMED's (CNMD) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CONMED's (CNMD) first-quarter earnings reflect strong segmental performance.
PacBio's (PACB) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
PacBio (PACB) sees strength in Q1 segmental revenues, led by robust consumable and instrument sales.
LHC Group (LHCG) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
LHC Group's (LHCG) first-quarter results benefit from organic growth in both home health as well as hospice admissions.
Cardinal Health (CAH) Q3 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results benefit from a solid performance in the Pharmaceutical segment.
BD (BDX) Beats on Q2 Earnings and Revenues, Revises FY22 View
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal second quarter.
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Revenue growth across the BSI and BEST businesses drove Bruker's (BRKR) first-quarter 2022 revenues.
Tandem Diabetes (TNDM) Q1 Earnings Lag Estimates, Sales View Up
by Zacks Equity Research
Robust pump shipments and growth in the installed customer base are driving Tandem Diabetes' (TNDM) first-quarter top line.
Cardiovascular Systems' (CSII) Q3 Earnings Top Estimates
by Zacks Equity Research
Cardiovascular Systems' (CSII) third-quarter revenues declined year over year due to lower Coronary and peripheral revenues.
NuVasive (NUVA) Q1 Earnings Beat Estimates, 2022 View Up
by Zacks Equity Research
Robust sales performance across all U.S. product lines drove NuVasive's (NUVA) Q1 top line.
Charles River (CRL) Q1 Earnings Top, Gross Margin Falls
by Zacks Equity Research
Charles River (CRL) Q1 results highlight 9.8% organic revenue growth, driven by strength across all three segments.
CVS Health (CVS) Q1 Earnings Top Estimates, '22 EPS View Up
by Zacks Equity Research
CVS Health (CVS) reports better-than-expected results for Q1, with robust segmental performance driving the top line.
Masimo's (MASI) Q1 Earnings Surpass Estimates, FY22 View Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments drive its Q1 sales.
Cerner (CERN) Q1 Earnings in Line, Revenues Lag Estimates
by Zacks Equity Research
Cerner's (CERN) first-quarter results benefit from gains across four of its business units.
PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results benefit from a solid performance at Discover & Analytics Solutions business.